Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Keros Therapeutics (KROS) EBT (2019 - 2025)

Keros Therapeutics (KROS) has disclosed EBT for 7 consecutive years, with -$25.0 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, EBT rose 45.38% year-over-year to -$25.0 million, compared with a TTM value of $91.9 million through Dec 2025, up 149.13%, and an annual FY2025 reading of $91.9 million, up 149.13% over the prior year.
  • EBT was -$25.0 million for Q4 2025 at Keros Therapeutics, down from -$8.7 million in the prior quarter.
  • Across five years, EBT topped out at $158.5 million in Q1 2025 and bottomed at -$53.0 million in Q3 2024.
  • Average EBT over 5 years is -$21.3 million, with a median of -$28.5 million recorded in 2022.
  • The sharpest move saw EBT crashed 501.46% in 2022, then soared 467.62% in 2025.
  • Year by year, EBT stood at -$4.9 million in 2021, then plummeted by 501.46% to -$29.7 million in 2022, then crashed by 56.32% to -$46.5 million in 2023, then grew by 1.57% to -$45.7 million in 2024, then surged by 45.38% to -$25.0 million in 2025.
  • Business Quant data shows EBT for KROS at -$25.0 million in Q4 2025, -$8.7 million in Q3 2025, and -$32.9 million in Q2 2025.